Evidence map›Paper›PMID 29536411›Full record

ArticleHuman cell2018

MiR-192-5p suppresses the growth of bladder cancer cells via targeting Yin Yang 1.

Decai Ji, Lining Jiang, Yingjie Li

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Emerging Role of MiR-192-5p in Human Diseases.Frontiers in pharmacology · 2021
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Decai JiFirst Urology, Cangzhou Central Hospital, No. 16, West of Xin Hua Street, Cangzhou, Hebei, China. dc_jdc@163.com.ORCID http://orcid.org/0000-0002-8423-1361
Lining JiangFirst Urology, Cangzhou Central Hospital, No. 16, West of Xin Hua Street, Cangzhou, Hebei, China.
Yingjie LiFirst Urology, Cangzhou Central Hospital, No. 16, West of Xin Hua Street, Cangzhou, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer has been identified as one of the most malignant cancers with high incidence and mortality. The underlying mechanisms by which regulate the tumorigenesis of bladder cancer deserve further investigation. Here, we found that miR-192-5p was downregulated in human bladder cancer cell lines and tissues. Overexpression of miR-192-5p significantly inhibited the growth of bladder cancer cells, while depletion of miR-192-5p exerted opposite effect. Bioinformatics analysis and molecular mechanism study identified that miR-192-5p targeted the transcription factor Yin Yang 1 (YY1) and decreased the expression level of YY1. Highly expressed YY1 attenuated the potential tumor suppressive function of miR-192-5p. The expression of miR-192-5p was negatively correlated with that of YY1 in bladder cancer tissues. These results indicated that miR-192-5p might serve as a promising target in bladder cancer diagnosis and therapy.

Indexed as

Molecular Targeted TherapyApoptosisCell Line, TumorCell SurvivalDown-RegulationFemaleGene ExpressionGene Expression Regulation, NeoplasticHumansMaleMicroRNAsMiddle AgedReal-Time Polymerase Chain ReactionTransfectionUrinary Bladder NeoplasmsYY1 Transcription FactorMicroRNAsMIRN192 microRNA, humanYY1 protein, humanYY1 Transcription FactorBladder cancerCell growthGene expressionmiR-192-5pYY1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.